VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BYAH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BYAHPark Ha Biological Technology Co., Ltd. Ordinary Shares
$1.15$42M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. BYAH
  4. Financial Ratios

Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) Financial Ratios

Latest Ratios: P/E Ratio 62.8x · EV/EBITDA 51.1x · ROE 38.0%. (2021–2024 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

BYAH Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2024FY 2023FY 2022FY 2021
Market Cap$42M————
Enterprise Value$42M————
P/E Ratio →62.84————
P/S Ratio17.72————
P/B Ratio20.01————
P/FCF48.24————
P/OCF43.94————

P/E links to full P/E history page with 30-year chart

BYAH EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2024FY 2023FY 2022FY 2021
EV / Revenue—————
EV / EBITDA51.11————
EV / EBIT52.57————
EV / FCF—————

BYAH Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2024FY 2023FY 2022FY 2021
Gross Margin91.8%91.8%87.4%73.5%66.6%
Operating Margin33.3%33.3%48.0%10.3%-53.8%
Net Profit Margin20.1%20.1%34.6%10.0%-52.1%

Return on Capital

MetricTTMFY 2024FY 2023FY 2022FY 2021
ROE38.0%38.0%146.6%127.3%—
ROA17.9%17.9%35.6%12.3%-81.6%
ROIC114.6%114.6%8595.4%——
ROCE61.5%61.5%201.4%131.1%—

BYAH Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2024FY 2023FY 2022FY 2021
Debt / Equity0.050.050.030.17—
Debt / EBITDA0.090.090.030.12—
Net Debt / Equity—-0.32-0.99-3.65—
Net Debt / EBITDA-0.58-0.58-0.83-2.41—
Debt / FCF—-0.55-9.65-0.38—
Interest Coverage———1015.59-419.58

Net cash position: cash ($547498) exceeds total debt ($70318)

BYAH Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2024FY 2023FY 2022FY 2021
Current Ratio1.871.871.750.960.41
Quick Ratio1.821.821.670.920.14
Cash Ratio0.360.360.830.240.06
Asset Turnover—0.771.090.761.57
Inventory Turnover2.732.733.245.410.98
Days Sales Outstanding—170.05105.50290.1331.25

BYAH Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2024FY 2023FY 2022FY 2021
Dividend Yield—————
Payout Ratio—————

Total Shareholder Return Metrics

MetricTTMFY 2024FY 2023FY 2022FY 2021
Earnings Yield1.6%————
FCF Yield2.1%————
Buyback Yield0.0%————
Total Shareholder Yield0.0%————
Shares Outstanding—$26M$26M$26M$26M

Key Metrics

Growth RegimeContracting
ProfitabilityStrong
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Geopolitical and Regulatory Exposure

Premium Multiples Amid Revenue Contraction

Based on current market data, the company trades at a P/E of 62.84 and a P/S of 17.72, which suggests that investors are pricing in significant growth expectations that appear disconnected from the reported 3.14% year-over-year revenue decline observed in recent financial filings.

The valuation multiples imply a high-growth trajectory that is not currently supported by the company's top-line performance. Investors should monitor whether these elevated ratios reflect a mispricing of the brand's niche franchise model or if the market is anticipating a structural turnaround that has yet to materialize in the financials.

Elite Margins Versus Operational Overhead

As reported in financial statements, the company maintains a robust 91.80% gross margin, yet the compression to a 33.32% operating margin suggests that significant SG&A expenditures are required to sustain the franchise-based distribution network, potentially limiting the scalability of the firm's current business model.

The wide gap between gross and operating margins indicates that the company's profitability is highly sensitive to the costs of maintaining its localized franchise relationships. This structure suggests that while the product itself commands premium pricing, the operational cost of supporting the distribution network may be a persistent drag on net profitability.

Conservative Capitalization Mitigates Financial Risk

According to the company's balance sheet, the negligible 0.05% debt-to-equity ratio indicates a highly conservative capital structure, which provides a significant buffer against interest rate volatility but may also suggest a lack of aggressive reinvestment strategies to drive future expansion in the competitive Chinese skincare market.

The near-absence of debt reflects a risk-averse management approach that is well-suited for the regulatory uncertainties inherent in the Chinese personal care sector. However, this lack of leverage warrants further investigation into whether the company is missing opportunities to optimize its capital structure to enhance shareholder returns.

Misapplication of Standard Valuation Metrics

The P/E ratio is frequently misapplied to this business model because it fails to account for the high proportion of non-operating income or tax artifacts common in US-listed Chinese holding companies, which can artificially inflate the perceived earnings quality of the Park Ha brand.

Analysts should prioritize EV/EBITDA or cash-flow-based metrics over P/E to better strip away the noise created by the company's complex cross-border structure. Relying solely on P/E risks overestimating the sustainability of the company's net income, especially given the lack of transparency regarding the accessibility of cash held within Chinese subsidiaries.

Download Financial Ratios Data

Includes 30+ ratios · 4 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

BYAH — Frequently Asked Questions

Quick answers to the most common questions about buying BYAH stock.

What is Park Ha Biological Technology Co., Ltd. Ordinary Shares's P/E ratio?

Park Ha Biological Technology Co., Ltd. Ordinary Shares's current P/E ratio is 62.8x. This places it at the 50th percentile of its historical range.

What is Park Ha Biological Technology Co., Ltd. Ordinary Shares's EV/EBITDA?

Park Ha Biological Technology Co., Ltd. Ordinary Shares's current EV/EBITDA is 51.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.

What is Park Ha Biological Technology Co., Ltd. Ordinary Shares's ROE?

Park Ha Biological Technology Co., Ltd. Ordinary Shares's return on equity (ROE) is 38.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 104.0%.

Is BYAH stock overvalued?

Based on historical data, Park Ha Biological Technology Co., Ltd. Ordinary Shares is trading at a P/E of 62.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Park Ha Biological Technology Co., Ltd. Ordinary Shares's profit margins?

Park Ha Biological Technology Co., Ltd. Ordinary Shares has 91.8% gross margin and 33.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Park Ha Biological Technology Co., Ltd. Ordinary Shares have?

Park Ha Biological Technology Co., Ltd. Ordinary Shares's Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.